STAT Summit: The State Of Biotech

New gene therapies cost millions of dollars each. Can we afford them? STAT reporter Adam Feuerstein discusses the state of biotech industry with Dr. Athena Countouriotis of Turning Point Therapeutics, Dr. Jeff Jonas of Sage Therapeutics, and Nick Leschly of Bluebird.